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CAR-NK cells may represent a valuable tool, complementary to CAR-T cells, in adoptive
immunotherapy of leukemia and solid tumors. However, gene transfer to human NK cells
is a challenging task, particularly with non-virus-based techniques. Here, we describe
a new procedure allowing efficient electroporation-based transfection of plasmid DNA,
including CAR and CCR7 genes, in resting or cytokine-expanded human NK cell
populations and NK-92 cell line. This procedure may offer a suitable platform for a safe
and effective use of CAR-NK cells in adoptive immunotherapy of cancer.
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INTRODUCTION
Cell-mediated immune responses play a central role in the control of infections and tumor growth.
In particular, cytotoxic T lymphocytes (CTL) and natural killer (NK) cells are important effectors
against solid tumors and leukemias (1, 2). In this context, both T and NK cells are known
to play a fundamental role in clearing tumor cells in patients with hematologic malignancies
receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) (3). Another important
cell-based immunotherapy is the use of autologous T cells that have been genetically engineered
with Chimeric Antigen Receptors (CAR-T cells) specific for tumor antigens. A substantial benefit
of this therapeutic approach has been shown by clinical trials, primarily in patients with lymphoid
malignancies refractory to chemotherapy or relapsing after allo-HSCT (4–6). However, clinical
trials employing CAR-T cell in solid tumors have not been so successful (7) mainly due to the
suppressive nature of the tumor microenvironment (8).
Recent studies indicated that also NK cells may be genetically engineered with CAR (9–12).
Notably, CAR-NK cells retain the expression of their activating and inhibitory receptors. Thus,
different from CAR-T cells, CAR-NK cells can still exert their “natural” anti-leukemia effect (9) in
case the tumor antigen targeted by CAR is downregulated (13). In addition, given their different
homing properties and the different patterns of cytokines/chemokines released upon activation,
CAR-NK cells may be complementary to CAR-T cells in tumor therapy and, possibly, safer with
respect to clinical implications, including the cytokine storm syndrome and neurotoxicity (14, 15).
Moreover, CAR-NK cells may potentially become an off-the-shelf tool, as they do not seem to
require a strict autologous HLA matching as T cells do (14).
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A successful CAR-based immunotherapy requires an efficient
transfer of the CAR transgene into the immune cells. To this
purpose, both viral transduction and non-viral transfection
methods in T and NK cells have been attempted. While the
use of CAR-NK cells may offer potential advantages, their
transfection is considerably less efficient as compared to T cell
transfection (16). Recent improvements in viral transduction
technology renewed the interest in developing strategies aimed
at potentiating NK cell activity through genetic engineering (16–
18). However, viral transduction requires dedicated facilities,
high costs and a complex preparation. Recently, electroporation
of mRNA has been proposed as an alternative method to viral
transduction although the short-time expression of the transgene
may represent a major limitation (19–21).
In the present study, we developed a new (virus-free) protocol
for NK cell electroporation using plasmid DNA that allows a
major improvement both in the transfection efficiency and in
cell viability. We could successfully transfect different reporter
genes (such as EGFP, YFP, Azuride) and functional genes (an
anti-CD19 CAR and a chemokine receptor, the CCR7 gene).
Our new protocol allows a safer and efficient way to genetically
manipulate NK cells, thus offering a novel valuable tool for
cancer immunotherapy.
MATERIALS AND METHODS
Human Samples
This study included 18 buffy coats collected from volunteer
blood donors admitted to the blood transfusion service of IRCCS
Bambino Gesù Pediatric Hospital after obtaining informed
consent. The Ethical Committee of IRCCS Bambino Gesù
Pediatric Hospital approved the study (825/2014) and conducted
in accordance with the ethical principles stated in the Declaration
of Helsinki.
Cells Lines and Cell Culture
NK-92 (malignant non-Hodgkin’s lymphoma), K562 (chronic
myelogenous leukemia, CD19−), Jurkat (acute T cell leukemia,
CD19−) Karpas 299 (Human Non-Hodgkin’s Ki-positive Large
Cell Lymphoma, CD19−), Nalm-8 (Lymphoblastic Leukemia,
CD19+) Raji (Burkitt’s Lymphoma, CD19+), and DAUDI
(Burkitt’s Lymphoma, CD19+) cell lines were purchased from
American Type Culture Collection (ATCC, Rockville, MD).
K562, Karpas 299, Jurkat, Nalm-8, Raji and Daudi cells were
cultured in RPMI 1640 supplemented with 2mM l-glutamine,
1% penicillin-streptomycin-neomycin mixture and 10% heat-
inactivated Fetal Calf Serum. For NK-92 20% of FCS and
50 ng/ml of recombinant human IL-2 (Proleukin; Chiron
Therapeutics, Emeryville, CA) were added at the culturemedium.
Peripheral blood mononuclear cell (PBMC) were obtained
from buffy coats after density gradient centrifugation over
Ficoll Lympholyte R©-H (Cederlane, Burlington, Canada). Highly
purified (≥ 98%) NK cells were subsequently obtained by
depletion of non-NK cells using the Miltenyi NK cell separation
kit (Miltenyi Biotech, Bergisch Gladbach, Germany), according
to the manufacturer’s instruction. To obtain polyclonal activated
NK cells, freshly isolated NK cells were cultured on 30Gy
irradiated PBMCs feeder cells in the presence of 600 U/mL
recombinant human IL-2 (Proleukin; Chiron Therapeutics,
Emeryville, CA) and 1.5 ng/mL phytohemagglutinin (PHA,
GIBCO Ltd) for the first week. The culture medium was RPMI
1640 (Euroclone, MI, IT) medium supplemented with 2mM
L-glutamine (Euroclone,MI, IT), 1% penicillin-streptomycin-
neomycin mixture (Euroclone,MI, IT), and 10% heat-inactivated
Fetal Calf Serum (FCS, Euroclone, MI, IT). Every 3–4 days NK
cells were expanded until the right exponential growth phase was
reached to perform experiments.
Plasmids
pmaxGFP (3,5 kb; Lonza) was used to setting up the
electroporation conditions. The following plasmids were
used for the experiments: pEGFP-N1 (BD Biosciences, San
Jose, CA) (4,7 kb) and pEGFP-N1-CCR7 (5,5 kb) (22); pLV-
Azuride (7,5 kb Addgene plasmid #36086); pCEP4YPet (10,9kb
Addgene plasmid #14032). The plasmids carrying the first and
second generation CAR were developed by Dr. C. Quintarelli.
Both plasmids have been designed to carry the cassette of
first or second generation CAR with specificity for the CD19
antigen. Single-chain variable fragment (scFv), derived from a
murine antibody of IgG (FMC63) class, was linked to human
CD8a hinge-transmembrane domain (CD8aTM) and CD3-ζ
to obtain a first generation CAR plasmid or CD8aTM, the
costimulatory domains 4-1BB (CD137) and CD3-ζ to obtain
a second generation of CAR plasmid. The sequence encoding
for a peptide derived from the human phosphoglycoprotein
CD34 (1CD34) was added as a trackable marker. All plasmids
were purified from Escherichia coli-transformed cells using
EndoFree Plasmid Maxi kit (Quiagen, Hilden, Germany), and
re-suspended in endotoxin- free water. Light absorption at
260 nm was used to determine the DNA concentration. Quality
of the plasmid purification was assessed by calculating the ratio
of light absorption at 260/280 and 260/230 nm.
Cell Electroporation
NK-92 cell line, freshly isolated (resting) or IL-2-activated NK
cells were electroporated with the Neon Transfection System
(Thermo Fisher Scientific, Waltham, Massachusetts, USA).
During the optimization process, a range of conditions for
different transfection parameters (DNA concentration, number
of cells, pulse settings) was tested. To determine the optimal
DNA amount, different plasmid concentrations were tested,
ranging from 50 to 200µg/ml. The Optimal Condition (OC)
was 120µg/ml. For the number of cells, (range from 2∗107
to 6∗107/ml) the OC was 4∗107/ml for both resting and Il-2-
expanded NK cells. We also adjusted the electroporation pulse
voltage and width. For both the first and the second pulse, a range
of voltage (from 1400 to 2300V for the first pulse and from 500
to 1000V for the second pulse) was tested and then the three best
voltages were used with a range of width (from 10 to 30ms for
the first pulse and from 50 to 300ms for the second pulse). For
the resting NK cells the OC of the first pulse resulted 2050V and
20ms followed by a second pulse of 500V and 100ms. We found
that the OC for the Il-2-expanded NK were a first pulse of 1850V
and 20ms and a second one of 500V and 100ms. For NK-92 cell
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line, we used a first pulse of 1650V and 20ms and a second one
of 500V and 100ms. For efficient electroporation of NK-92 and
IL-2-expanded NK cells, different electroporation buffers were
tested. In particular, different amount of: DMSO (Sigma-Aldrich,
St. Louis, USA) (from 0.01 to 10%), sucrose (Sigma-Aldrich,
St. Louis, USA) (from 10 to 200 nM), magnesium (Sigma-
Aldrich, St. Louis, USA) (from 0.1mM to 20mM) and dextran
(Sigma-Aldrich, St. Louis, USA) (from 2.5µg/ml to 10µg/ml)
were diluted in Optimem medium (Thermo Fisher Scientific,
Waltham, Massachusetts, USA, henceforth mentioned as buffer
O). The components were added individually or in a combination
of two or three to buffer O. For the pre-electroporation step,
the same buffers were used for a washing step of 5min at 300 g
before electroporation. Buffer O with the 0,1% of buffer CD was
the OC. All steps were performed at room temperature. After
electroporation, cells were grown on a 96-well round bottom
plate in 100 µl of RPMI 1640 medium supplemented with 2mM
l-glutamine, 600 U/mL recombinant human IL-2 and 20% heat-
inactivated FCS. Viability and transfection efficiencies were tested
24 h after electroporation. After the electrotransfer, cells were
analyzed by flow cytometry on a Cytoflex S (Beckman Coulter,
Brea, CA, USA) flow cytometer to evaluate the levels of GFP
expression. The number of living cells was evaluated as PI or
DAPI (Sigma-Aldrich, St. Louis, USA) negative. The percentage
of surviving cells was determined 24 h after electroporation
and expressed as a percentage of the number of cells counted
in the control. Unless otherwise specified, the percentage of
GFP-positive cells reported in the figures was calculated as the
percentage of surviving cells expressing GFP.
Migration Assay
Chemotaxis of NK cells was measured by migration through a
polycarbonate filter with a 3.0-µm pore size in 24-well trans-
well chambers (Corning Costar). The assay medium consisted
of RPMI 10% FCS. Five hundred microliter of assay medium,
containing 250 ng/mL of CCL19 and CCL21 (PeproTech,
London, United Kingdom), were added to the lower chamber.
Five hundred microliter of assay medium with no addiction was
used as a control for spontaneous migration. Then, 5 × 105 NK
cells, electroporated with pEGFP-N1-CCR7 or with the empty
vector (pEGFP-N1), were added to the upper chamber in a total
volume of 350 µL of RPMI 10% FCS. After 3-h incubation at
37◦C, NK cells migrated to the bottom chamber were counted by
optical microscopy (Leica Microscopy, Wetzlar, Germany) with
a 25 × objective. The number of spontaneously migrated cells
was subtracted from the total number of migrated cells. Values
are given as the chemotactic index compared to the migration
of unstimulated NK cells. As further confirmation, migrated cells
were also counted by flow cytometry (absolute count) (Cytoflex
S, Beckman Coulter, Brea, CA, USA).
Analysis of Cytotoxic Activity
In all experiments NK-cell cytotoxicity was analyzed by
incubating of the indicated NK-cell transfectant with the target
cell lines at an effector-to-target (E:T) ratio ranging from 10:1 to
0,25:1. Cytotoxicity was assessed using a flow cytometric assay
for NK-cell killing developed by McGinnes (23) modified as
follow: target cells were stained with 5µM Cell Tracker Green
(CMFDA, Invitrogen, Thermo Fisher Scientific), incubated with
NK cells at 37◦C for 4 h and then propidium iodide (Sigma-
Aldrich, St. Louis, USA) was added. Live target cells were
identified as CMFDA+ PI− whereas dead target cells (Td) were
CMFDA+ PI+. Specific lysis was calculated as Td of target cells
cultured with effector cells – Td of target cells cultured without
effector cells.
Flow Cytometry Analysis and
Measurement of Cell Viability
To verify the purity of NK separation, NK cells were stained with
anti-CD56-PC7 (Beckman Coulter, Brea, CA, USA, Clone N901
NKH-1) anti-CD3-ECD (Beckman Coulter, Clone UCHT1) anti-
CD14-ECD (Beckman Coulter, Clone RMO52) anti-CD19-ECD
(Beckman Coulter, Clone J3-119) antibodies. To study the
expression of NK receptors after electroporation, NK cells were
stained with antibodies specific for NKG2a PE (BeckmanCoulter,
Clone Z199); CD158 a/h (Clone EB6B),CD158b1/b2/j (Clone
GL183),CD158e1/e2 (Clone Z27.3.7) APC (Beckman Coulter);
NKp46 (Clone BAB281), NKp44 (Clone Z231), NKp30 (Clone
Z25) PE (Beckman Coulter); NKG2D PE/Dazzle594 (Biolegend,
San Diego, CA, Clone 1D11); DNAM1 APC (Biolegend, Clone
11A8); Perforin PE (Biolegend, Clone dG9); CD11a vioblue
(Miltenyi Biotech, Bergisch Gladbach, Germany, Clone REA378)
NKG2c viobright FITC (Miltenyi Biotech, Clone REA205)
CD57 vioblue (Miltenyi Biotech, Clone TB03) CD34-APC
APC (R&D Systems, clone QBend10). For detection of surface
markers, NK cells were incubated for 20min at 4◦C. For
detection of intracellular markers, NK cells were treated with
the BD Cytofix/cytoperm kit (BD Biosciences, Erembodegem,
Belgium) according to manufacturer’s protocols. NK cell samples
were acquired using the Beckman Coulter Cytoflex S flow
cytometer and analyzed with the CytExpert 2.3 or Kaluza
software 2.1 (Beckman Coulter, Brea, CA, USA). For cell sorting,
electroporated CCR7-GFP+ NK cells were sorted to a purity of≥
98% with the MoFlo Astrios sorter (Beckman Coulter) using the
Summit software (Beckman Coulter).
Intracellular Analysis of IFN-γ Production
IFN-γ expression was analyzed by incubating of the indicated
NK-cell transfectant with the K562 cell line in 1:1 ratio for 4 h.
Intracellular eFluor 450 anti-human IFN-γ (Invitrogen, Thermo
Fisher Scientific Clone 4S.B3.) staining was then performed using
a Fix & PermCell Permeabilization Kit (Invitrogen) following the
manufacturer’s instructions.
Statistical Analysis
Statistical analyses were performed using the GraphPad Prism
6.0 (La Jolla, CA, USA) software. Values were expressed as mean
± SD. P-values were calculated with Wilcoxon test. For multiple
comparison analysis Bonferroni correction was applied. P< 0.05
were considered statistically significant. ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001.
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RESULTS
Optimization of the Electroporation
Protocol for an Efficient Transfection of NK
Cells
A first set of experiments was aimed at increasing
the efficiency of NK cell transfection using a plasmid
encoding the GFP reporter gene (pmaxGFP). In order to
optimize an electroporation protocol for freshly isolated
(referred to as “resting”) NK cells, we started by modifying
classical parameters (Figure 1A) including numbers of
cells per reaction, voltage, number of pulses applied and
concentration of plasmid DNA taking advantage of the
NeonTM Transfection System (Thermo Fisher Scientific).
Supplementary Figure 1A shows the optimal protocols after
each optimization step.
Although the quantity of DNA has a small impact on
the overall efficiency and no significant effects on cells
viability (Figure 1B upper panel protocol #2), testing a range
of concentrations spanning from 50 to 200µg/ml, the best
results were achieved with 120µg/ml of DNA. Subsequently,
we decided to investigate the effect of cell numbers on NK
cells transfection efficiency. Notably, the number of cells used
in each reaction was extremely important (Figure 1B upper
panel, protocol#3) with the optimal condition (OC) being
4∗107 cells/ml (in a range from 2∗107 to 6∗107 cells /ml).
Indeed, a lower cell number resulted in a reduced viability,
whereas a higher cell number was associated with a decrease
in transfection efficiency, even with scaled amount of DNA
(data not shown). Notably, the optimization of cell number
led to a 10-fold increase of cell viability and to a 3-fold
increase of transfection efficiency (Figure 1B upper panel,
protocol #3).
Pulse voltage and width were the other parameters considered.
One of the best approach for difficult-to-electroporate cells
is the application of two pulses (24). The first one at high
voltage and short width, that induces the openings of the cell
membrane pores, and the second one, at low voltage but with
long width, that drives the DNA into the cells trough the pores
on the cell membrane. For both pulses, we first analyzed a
range of voltage (from 1400 to 2300V for the first one and
from 500 to 1000V for the second one) and then the 3 best
voltages were further tested with a range of width (from 10
to 30ms for the first pulse and from 50 to 300ms for the
second pulse). Our data show that OC for the first pulse
was 2050V for 20ms followed by a second pulse of 500V
for 100ms (Supplementary Figure 1A).
As summarized in Table 1, we were able to define optimal
conditions for efficient transfection of resting NK cells (4 × 106
cells/ml and 120µg/ml DNA, applying a first pulse of 2050V
for 20ms immediately followed by a second pulse of 500V for
100ms). This procedure allows reaching ∼50% of cell viability
and∼50% of transfection efficiency (Figure 1C left panel). These
results represent a major improvement in NK cell transfection.
Indeed, using this protocol we were able to obtain a 5-fold
higher efficiency, as compared to the other procedures described
so far (17).
In-vitro expanded NK cells are widely used in clinical trials
due to their stronger anti-tumor cytolytic activity as compared to
resting NK cells.
Thus, we attempted to apply the same optimization steps to
improve the transfection of IL-2-expanded NK cells. However,
as reported in Figure 1B (lower panel), neither cell viability
nor transfection efficiency resulted satisfactory (14 and 20%,
respectively, protocol #5). Previous reports have shown that
the addition of different compounds in the electroporation
buffer affected both cell viability and electroporation efficiency
(25–27). Therefore, to improve the transfection efficiency of
IL-2-expanded NK cells, different buffers were analyzed for
electroporation. DMSO (from 0.01 to 10%), sucrose (from 10 to
200 nM), magnesium (From 0.1 to 20mM) and dextran (From
2.5 to 10µg/ml) were diluted, at different concentration, in
Optimem medium (henceforth mentioned as buffer O). The
components were added individually, or in a combination of two
or three, to buffer O. The buffer O on its own demonstrated
to be beneficial for both transfection efficiency and cell viability
(Figure 1B lower panel protocol #6), but not in any other
combination (data not shown).
In addition, we assessed the effects of these buffers in
the washing step that is a critical point for transfection
efficiency, as highlighted by the manufacturer. Although Buffer
OD (0.01% DMSO in buffer O) improved the efficiency, on
the other hand it determined a decrease in cell viability
(Figure 1B lower panel protocol #7). With Buffer OD we
also observed a higher variability in NK cell transfection
efficiency among the different donors analyzed. A basis to
understanding the high variability among donors is the finding
that DMSO stabilizes the pores induced by an electric field
preferentially in the presence of a fixed amount of cholesterol
in the lipid bilayer (28). In light of this notion, the washing
step with 0.1% of saturated cholesterol-DMSO in buffer O
(buffer CD) determined an increase in both viability and
transfection efficiency (Figure 1B lower panel protocol #8
and Supplementary Figure 1B). As shown in Figure 1C (right
panel), the use of these buffers, combined with a first pulse
of 1820V for 20ms, resulted in a sharp increase in cell
viability (up to 58%). Moreover, using these conditions the
efficiency of transfection raised up to 51% 24 h after transfection.
Notably, the latter protocol proved to be suitable also for
electroporation of NK-92, a human NK cell line widely used
in clinical trials (16), reaching up to 60% of transfection
efficiency (Figure 1D). Importantly, this new procedure did
not alter the expression of both surface NK receptors and
cytoplasmic perforin (Figure 2A) in IL-2 activated NK cells.
In addition, NK cells maintained the capability of producing
interferon-γ (Figure 2B).
Plasmids of Different Size Can Be
Efficiently Transfected in NK Cells
In the development of our transfection procedure, we used
a plasmid DNA of small size (≈3.5 Kb). Since the size of
the DNA vectors may influence the transfection efficiency
(29), we tested whether the new method was suitable for
Frontiers in Immunology | www.frontiersin.org 4 April 2019 | Volume 10 | Article 957
Ingegnere et al. Efficient NK Cells Non-viral Transfection
FIGURE 1 | Development of a new transfection method for human NK cells. (A) Schematic steps of NK cell electroporation-based transfection methods. The
asterisks (*) indicate the step in which we obtained the higher efficiency and viability (Optimal Condition O.C.) of resting or activated NK cells. (B) Percentages of cell
viability and transfection efficiency obtained for the different protocols (from #1 to #8) applied to improve NK cell electroporation. Error bars indicate Standard Deviation
(SD). P-values were calculated comparing each protocol with the previous one. *p < 0.05, **p < 0.01, and ***p < 0.001. (C,D) GFP expression in electroporated
resting NK cells (C, left panel), Il-2 activated NK cells (C, right panel) and in NK92 cell line (D). One representative experiment out of 4 performed is shown.
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TABLE 1 | Table showing the starting electroporation condition (manufacture protocol) compared with the optimal condition determined for resting and IL-2 activated
NK cells.
No. of cells First pulse Second pulse Wash buffer Electroporation buffer
Manufacture suggested 2*107 /ml 2100V / 20ms _ PBS 1X Buffer R
Resting NK cells O.C. 4*107 /ml 2050V / 20ms 500V/100ms PBS 1X Buffer R
Expanded NK cells O.C. 4*107 /ml 1820V / 20ms 500V/100ms Buffer CD Buffer O
FIGURE 2 | Characterization of NK cells after electroporation (A) Cytofluorimetric analysis of NK cell receptors and perforin expression on IL-2-activated NK cells at 5
days after electroporation in FMO control (black filled profiles), untrasfected (gray filled profiles) or with pmaxGFP plasmid (black empty profiles). A representative
experiment out of 3 is shown. (B) Percentages of interferon-gamma (IFNγ) positive untransfected- and pmaxGFP electroporated-NK cells. Unstimulated (black bars)
are compared with K562 stimulated (white bars) NK cells. (C) Transfection with different plasmid sizes in NK cells. Percentage of viability and efficiency after
electroporation of activated NK cells with plasmids of different size. ***p < 0.001, **p < 0.01 and *p < 0.05. (D) Persistence of transfected genes and (E) viability of
NK cells at different culture intervals after electroporation. Six experiments performed.
the transfection of plasmids of larger size. To this end, IL-
2 expanded NK cells were electroporated with four plasmids
of different size, ranging from 3.5 to 12 kb. With all the
analyzed plasmids we obtained a substantial increase of cell
transfection, ranging from 2.5- to 5-fold compared to the
standard electroporation protocol (indicated as “manufacture”)
even though the overall efficiency varied with the different
plasmids (Figure 2C).
Positive Transfected Cells Can Be
Detected Up to 15 Days After
Electroporation
We next analyzed the persistence of the transfected genes into the
electroporated NK cells. Notably, even after 5 days the percentage
of transfected cells did not change (Figure 2D) and the overall
viability of the culture increased up to 85 % (Figure 2E).
Remarkably, even after 10 days of culture only a 10% loss of
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FIGURE 3 | Electroporation of a functional CAR-antiCD19 transgene in NK cells increases their cytolytic activity. (A) Schematic representation of the different domains
of the two CAR constructs. (B) Representative gating strategy used to test the electroporation efficiency of I and II generation CAR constructs in the different NK cell
populations. (C) Electroporation efficiency of CD19+CAR plasmid in untransfected, mock-transfected and CAR-transfected activated NK cells. CAR expression was
evaluated on DAPI-negative live cells using the delta (1) CD34 marker. Cytometric profiles of unstained (empty profile), isotype stained (gray profile) and anti-1CD34
mAb stained (black profile) NK cells are shown. (D) Percentage of cytotoxicity was evaluated by flow cytometry on propidium iodide (PI) positive target cells. CD19−
cell lines (upper panel) and CD19+ (lower panel) were used as target cells. Effector: Target (E:T) ratios are indicated. A representative experiment out of 3 performed
is shown.
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cells positive for the transfected gene was detected. A relevant
reduction of the percentage of positive cells occurred after 15 days
of culture.
The Expression of Anti-CD19 CAR in IL-2
Expanded NK Cells Strongly Increases
Their Cytolytic Activity Against CD19+
Tumor Targets
We analyzed plasmids encoding for transgenes specific for
a first (I) and a second (II) generation CAR recognizing
the B cell antigen CD19 (Figure 3A). As reported, mRNA
electroporation of CARs did not preferentially target different
NK cell populations (30). Thus, we tested if with our
protocol we could obtain different transfection efficiency for
the various NK subpopulations. As illustrated in Figure 3B,
CAR expression was analyzed in resting NK cells 24 h after
electroporation. The efficiency of the two constructs was similar
(Figure 3B upper right panel). No differences of CAR expression
were observed among the NK cells populations analyzed
(Supplementary Figure 2). Considering that in vitro expanded
NK cells are those used for cell immunotherapy, we focused
our experiment on these cells. IL-2-expanded NK cells were
efficiently transfected with the second generation CAR plasmid
(9.5 Kb plasmid length). The percentage of transfected cells
was ∼40% (Figure 3C). Cell viability, measured 24 hours after
electroporation, was similar to that obtained in experiments with
pmaxGFP (i.e., ∼60%; data not shown). We then assessed the
cytolytic activity of CAR-NK cells 5 days after electroporation
since, at this time point, the viability of the cell cultures increased,
while the percentage of cells expressing the transgene remained
stable (Figures 2D,E). We tested different target CD19+ cell lines
including DAUDI, RAJI and NALM-18. As a negative control,
we used different CD19− cell lines, such as K562, Jurkat and
Karpas. On one hand, as shown in Figure 3D upper panel, no
major changes in the cytolytic activity between Mock- and CAR-
electroporated NK cells against all the CD19− cell lines could
be observed. However, NK cells displayed different ability to kill
these 3 cell lines, thus K562 showed the maximal susceptibility
to lysis, while Karpas, which were virtually resistant to both
mock and CAR-electroporated NK cells. On the other hand,
CAR-NK cells displayed a higher cytolytic activity against all the
CD19+ tumor cell lines tested (Figure 3D lower panel). These
data clearly indicate that the anti-CD19 CAR transfection confers
to NK cells a specific cytolytic activity against CD19+ target
cells. Accordingly, these CAR-NK cells may represent suitable
candidates for adoptive cell immunotherapy against CD19+
hematologic malignancies.
NK Cells Transfected With the CCR7
Transgene Show Increased Migratory
Properties
The surface expression of chemokine receptors is required for cell
migration. In this context, NK (or T) cells expressing transgenes
encoding for appropriate chemokine receptors may be addressed
to tumor sites (31), for example, lymph nodes infiltrated with
tumor metastases. Since CCR7+ cells migrate to lymph nodes
FIGURE 4 | NK cells transfected with CCR7 plasmid acquire migratory
capability. (A) Comparative expression of CCR7-GFP on DAPI-negative live
IL-2-activated NK cells using the new protocol and the manufactured protocol
(right panel). A representative experiment (left panel) out of 4 is shown (B)
Migration index of CCR7+ and mock-electroporated NK cells derived from 5
different donors. ***p < 0.001. (C) Schematic reppresentation of the CCR7
construct.
in response to CCL19 and CCL21, we investigated whether an
expression vector encoding CCR7 fused with GFP (pCCR7-
eGFP; Figure 4C) could be efficiently transfected in NK cells
by applying our new protocol. Although cell viability resulted
similar to that of our previous experiments, the transfection
efficiency with pCCR7-eGFP was lower compared to pmaxGFP
or CAR (∼20%; Figure 4A left panel). Notably, even a lower
transfection efficiency was obtained for the same plasmid by
using a standard (“manufactured”) electroporation protocol
(∼4%; Figure 4A right panel). Thus, also in this case, the
transfection efficiency using our protocol resulted∼5-fold higher
than that obtained with the manufacture procedure (Figure 4A
right panel). It is conceivable that the lower transfection
efficiency of pCCR7-eGFP may reflect intrinsic properties of
the pCCR7 vector. We next assessed the migration capability of
CCR7-transfected NK cells in response to CCL19 and CCL21
chemokines. As shown in Figure 4B, purified CCR7+ NK cell
transfectants migrate more efficiently than mock-transfected NK
cells (CCR7−), displaying a 6 fold increase in migration capacity.
DISCUSSION
Our present study provides a novel important tool for
a successful adoptive immunotherapy of cancer using NK
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cells transfected with CAR or chemokine receptors, using a
non-viral method.
The development of this new methodology allowed a great
improvement of the efficiency of NK cell electroporation with
plasmids of different size. Importantly, anti-CD19-CAR and
CCR7 conferred to NK cells an up to 5 fold increase in killing of
CD19+ tumor cells and a 6 fold increase of migratory capability
in response to CCL19 or CCL21, respectively.
Although the efficiency of DNA electroporation and viability
of transfected cells are lower than those obtained with mRNA
electroporation, our method opens new perspectives. Indeed,
we show that the transient DNA electroporation leads to a
more durable persistence of the transfected genes (up to 15
days). Moreover, while mRNA electroporation could be only
transient, the DNA electroporation may allow a stable integrated
gene transfer. More generally, our protocol could be applied
to improve the efficiency of any electroporation-based transfer
of different molecules (DNA, siRNA, mRNA, or proteins) into
NK cells. This method was developed using plasmids encoding
for reporter genes (i.e., pmaxGFP), and successfully applied to
the transfection and functional expression of plasmids encoding
transgenes of major relevance for NK cell-mediated tumor cell
killing and for NK cell migration. Regarding the migratory
capability, the expression of CCR7 is known to promote NK cell
migration primarily toward lymph nodes (32) (where CCL19 and
CCL21 are primarily produced). However, transfection of other
chemokine (or homing) receptors may induce NK cell migration
to different tissues and tumor sites (33, 34). An attractive
possibility is the development of double transfectants, allowing
to address CAR-NK cells where needed. Attempts toward this
goal are in progress in our lab. Importantly, the extension of our
approach to CAR targeting antigens expressed by solid tumors
may provide a valid tool for immuno-therapy of established
tumors and prevention of their spreading and metastasis (35).
Such acquired functional capabilities are of particular relevance
because CAR-NK cells represent suitable candidates for cell-
based adoptive therapies to target different solid tumors.
In conclusion, the method of NK cell transfection described in
our present study is highly efficient, does not require expensive
dedicated structures necessary for viral transduction and avoids
possible risks associated with the use of viral vectors. Importantly,
it may be applied to NK cells or NK-92 cell line, greatly
improving their anti-tumor activity and providing a newNK cell-
based platform for new protocols of adoptive immuno-therapy
of cancer.
ETHICS STATEMENT
The Ethical Committee of IRCCS Bambino Gesù Pediatric
Hospital approved the study (825/2014).
AUTHOR CONTRIBUTIONS
TI designed and performed research, interpreted data, and wrote
the article. FM, FB, and NT performed experiments. AP, CC,
and FL reviewed the manuscript. CQ and BD developed CAR
constructs and revised the manuscript. PV and LM designed
research and wrote the paper.
FUNDING
The present study has been supported by the following grants:
Associazione Italiana per la Ricerca sul Cancro (AIRC) IG
2014 Id. 15283 (LM), IG 2017 Id. 19920 (LM), Special
Project 5X1000 no. 21147 (LM), and Ministero della Salute
GR-2013-02356568 (PV). NT is recipient of a fellowship awarded
by AIRC.
ACKNOWLEDGMENTS
We thank Ezio Giorda and the Flow Cytometry core facility of
IRCCS Bambino Gesù Children’s Hospital.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.00957/full#supplementary-material
REFERENCES
1. Moretta L, Pietra G, Vacca P, Pende D, Moretta F, Bertaina A, et al. Human
NK cells: From surface receptors to clinical applications. Immunol Lett. (2016)
178:15–9. doi: 10.1016/j.imlet.2016.05.007
2. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural
killer cell? Nat Immunol. (2002) 3:6-8. doi: 10.1038/ni0102-6
3. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC,
Moretta A. Killer Ig-like receptor-mediated control of natural
killer cell alloreactivity in haploidentical hematopoietic stem cell
transplantation. Blood. (2011) 117:764–71. doi: 10.1182/blood-2010-08-
264085
4. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C,
Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for
acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-
escalation trial. Lancet. (2015) 385:517–28. doi: 10.1016/S0140-673661403-3.
5. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al.
Tisagenlecleucel in children and young adults with B-cell lymphoblastic
leukemia. N Engl J Med. (2018) 378:439–48. doi: 10.1056/NEJMoa1709866
6. Schuster SJ, Svoboda J, Chong EA, Nasta SD,Mato AR, AnakO, et al. Chimeric
antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. (2017)
377:2545–54. doi: 10.1056/NEJMoa1708566
7. LimWA, June CH. The principles of engineering immune cells to treat cancer.
Cell. (2017) 168:724–40. doi: 10.1016/j.cell.2017.01.016
8. Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM,Mehrotra S, Paulos CM.
CAR T cells in solid tumors: blueprints for building effective therapies. Front
Immunol. (2018) 9:1740. doi: 10.3389/fimmu.2018.01740
9. Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin
Immunol. (2017) 31:37–54. doi: 10.1016/j.smim.2017.07.009
10. Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, et al.
Advantages and applications of CAR-expressing natural killer cells. Front
Pharmacol. (2015) 6:21. doi: 10.3389/fphar.2015.00021
Frontiers in Immunology | www.frontiersin.org 9 April 2019 | Volume 10 | Article 957
Ingegnere et al. Efficient NK Cells Non-viral Transfection
11. Rezvani K, Rouce RH. The Application of natural killer cell
immunotherapy for the treatment of cancer. Front Immunol. (2015)
6:578. doi: 10.3389/fimmu.2015.00578
12. Shimasaki N, Campana D. Natural killer cell reprogramming with
chimeric immune receptors. Methods Mol Biol. (2013) 969:203–20.
doi: 10.1007/978-1-62703-260-5_13
13. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy.
Cancer Discov. (2018) 8:1219–26. doi: 10.1158/2159-8290.CD-18-0442
14. Siegler EL, Zhu Y, Wang P, Yang L. Off-the-shelf CAR-NK cells
for cancer immunotherapy. Cell Stem Cell. (2018) 23:160–1.
doi: 10.1016/j.stem.2018.07.007
15. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical
and biological correlates of neurotoxicity associated with CAR T-cell therapy
in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. (2018)
8:958–71. doi: 10.1158/2159-8290.CD-17-1319
16. Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer
cells for cancer immunotherapy. Mol Ther. (2017) 25:1769–81.
doi: 10.1016/j.ymthe.2017.06.012
17. Carlsten M, Childs RW. Genetic Manipulation of NK cells for
cancer immunotherapy: techniques and clinical implications.
Front Immunol. (2015) 6:266. doi: 10.3389/fimmu.2015.
00266
18. Kellner JN, Cruz CR, Bollard CM, Yvon ES. Gene modification of human
natural killer cells using a retroviral vector. Methods Mol Biol. (2016)
1441:203–13. doi: 10.1007/978-1-4939-3684-7_17
19. Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, et al.
Comparison of mRNA and lentiviral based transfection of natural killer
cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk
Lymphoma. (2012) 53:958–65. doi: 10.3109/10428194.2011.634048
20. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH,
Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human
haploidentical NK cells in patients with cancer. Blood. (2005) 105:3051–7.
doi: 10.1182/blood-2004-07-2974
21. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P,
et al. A clinically adaptable method to enhance the cytotoxicity of natural
killer cells against B-cell malignancies. Cytotherapy. (2012) 14:830–40.
doi: 10.3109/14653249.2012.671519
22. Marcenaro E, Cantoni C, Pesce S, Prato C, Pende D, Agaugue S, et al.
Uptake of CCR7 and acquisition of migratory properties by human
KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines:
regulation by KIR/HLA-class I interaction. Blood. (2009) 114:4108–16.
doi: 10.1182/blood-2009-05-222265
23. McGinnes K, Chapman G, Marks R, Penny R. A fluorescence NK assay using
flow cytometry. J Immunol Methods. (1986) 86:7–15.
24. Demiryurek Y, Nickaeen M, Zheng M, Yu M, Zahn JD, Shreiber
DI, et al. Transport, resealing, and re-poration dynamics of
two-pulse electroporation-mediated molecular delivery. Biochim
Biophys Acta. (2015) 1848:1706–14. doi: 10.1016/j.bbamem.2015.
04.007
25. Melkonyan H, Sorg C, Klempt M. Electroporation efficiency in mammalian
cells is increased by dimethyl sulfoxide (DMSO). Nucleic Acids Res.
(1996) 24:4356–7.
26. Golzio M, Mora MP, Raynaud C, Delteil C, Teissie J, Rols MP.
Control by osmotic pressure of voltage-induced permeabilization
and gene transfer in mammalian cells. Biophys J. (1998) 74:3015–22.
doi: 10.1016/S0006-3495(98)78009-9
27. Mussauer H, Sukhorukov VL, Zimmermann U. Trehalose improves survival
of electrotransfected mammalian cells. Cytometry. (2001) 45:161–9. doi: 10.
1002/1097-0320(20011101)45:3<161::AID-CYTO1159>3.0.CO;2-7
28. Fernandez ML, Reigada R. Effects of dimethyl sulfoxide on lipid membrane
electroporation. J Phys Chem B. (2014) 118:9306–12. doi: 10.1021/jp503502s
29. Williams JA. Improving DNA vaccine performance through vector design.
Curr Gene Ther. (2014) 14:170–89. doi: 10.2174/156652321403140819122538
30. Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D,
et al. Intrinsic functional potential of NK-cell subsets constrains retargeting
driven by chimeric antigen receptors. Cancer Immunol Res. (2018) 6:467–80.
doi: 10.1158/2326-6066.CIR-17-0207
31. Daher M, Rezvani K. Next generation natural killer cells for cancer
immunotherapy: the promise of genetic engineering. Curr Opin Immunol.
(2018) 51:146–53. doi: 10.1016/j.coi.2018.03.013
32. Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, et al. Efficient
mRNA-based genetic engineering of human NK cells with high-affinity CD16
andCCR7 augments rituximab-inducedADCC against lymphoma and targets
NK cell migration toward the lymph node-associated chemokine CCL19.
Front Immunol. (2016) 7:105. doi: 10.3389/fimmu.2016.00105
33. Kremer V, Ligtenberg MA, Zendehdel R, Seitz C, Duivenvoorden A,
Wennerberg E, et al. Genetic engineering of human NK cells to express
CXCR2 improves migration to renal cell carcinoma. J Immunother Cancer.
(2017) 5:73. doi: 10.1186/s40425-017-0275-9
34. Levy ER, Carlsten M, Childs RW. mRNA transfection to improve
NK cell homing to tumors. Methods Mol Biol. (2016) 1441:231–40.
doi: 10.1007/978-1-4939-3684-7_19
35. Huergo-Zapico L, Parodi M, Cantoni C, Lavarello C, Fernandez-Martinez
JL, Petretto A, et al. NK-cell editing mediates epithelial-to-mesenchymal
transition via phenotypic and proteomic changes in melanoma cell lines.
Cancer Res. (2018) 78:3913–25. doi: 10.1158/0008-5472.CAN-17-1891
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Ingegnere, Mariotti, Pelosi, Quintarelli, De Angelis, Tumino, Besi,
Cantoni, Locatelli, Vacca and Moretta. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 10 April 2019 | Volume 10 | Article 957
